CCFT 交易所
DUBAICAT EXCHANGES
A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccination
Scientists from the International Agency for Research on Cancer (IARC) and partner institutions h...
12.11.2024
Read more
Leveraging single-dose human papillomavirus vaccination dose-efficiency to attain cervical cancer elimination in resource-constrained settings
In a new paper, researchers from the International Agency for Research on Cancer (IARC) show that...
12.11.2024
Read more
Large IARC contingent to present at IPVC 2024 and host session on cervical cancer screening
Scientists from the International Agency for Research on Cancer (IARC) will attend the 36th Inter...
11.11.2024
Read more
IARC Newsletter: November 2024 issue now available
The International Agency for Research on Cancer (IARC) is pleased to share the November 2024 issu...
11.11.2024
Read more